Market Research Logo

Xeltis AG - Product Pipeline Analysis, 2018 Update

Summary

Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to replace defective heart valves and blood vessels. ETR enables the patient’s natural healing system to develop tissue that spreads into the heart valve of Xeltis, building a new and natural valve inside with full functionality. The implants of Xeltis get absorbed by the body in the course of time. The company also operates research and development centers, manufacturing facility in Eindhoven, the Netherlands. Xeltis is headquartered in Zurich, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Xeltis AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Xeltis AG Company Overview
Xeltis AG Company Snapshot 4
Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview
Xeltis AG – Pipeline Analysis Overview 6
Xeltis AG - Key Facts 6
Xeltis AG - Major Products and Services 7
Xeltis AG Pipeline Products by Development Stage 8
Xeltis AG Ongoing Clinical Trials by Trial Status 10
Xeltis AG Pipeline Products Overview 12
Endogenous Tissue Restoration (ETR) Cardiovascular Graft 12
Endogenous Tissue Restoration (ETR) Cardiovascular Graft Product Overview 12
Transcatheter Aortic Heart Valve 13
Transcatheter Aortic Heart Valve Product Overview 13
Xeltis Pulmonary Valve 14
Xeltis Pulmonary Valve Product Overview 14
Xeltis Pulmonary Valve Clinical Trial 15
Xeltis AG - Key Competitors 17
Xeltis AG - Key Employees 18
Xeltis AG - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Xeltis AG, Recent Developments 20
Jun 25, 2018: The Children’s Hospital of Pittsburgh of UPMC joins the Xplore-2 trial 20
Jun 22, 2018: Children’s Hospital Los Angeles joins the Xplore-2 Study 20
Jun 13, 2018: Xeltis restorative technology for aortic valves at ISMICS 20
Jun 01, 2018: Preliminary Xplore-1 data show promise at ECHSA 20
May 30, 2018: Preliminary Xplore-1 data at ECHSA 21
May 22, 2018: Xeltis aortic valve program in focus at EuroPCR 21
May 14, 2018: Xeltis’ restorative technology at ICTEHV 21
Apr 13, 2018: Xeltis’ restorative aortic valves show promise at HVS 21
Apr 06, 2018: Xeltis’ restorative aortic valves at HVS 22
Nov 01, 2017: Xeltis’ Aortic Valve Preclinical Results Shared at TCT 2017 22
Appendix 23
Methodology 23
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview 4
Xeltis AG Pipeline Products by Equipment Type 5
Xeltis AG Pipeline Products by Indication 5
Xeltis AG Ongoing Clinical Trials by Trial Status 5
Xeltis AG, Key Facts 6
Xeltis AG, Major Products and Services 7
Xeltis AG Number of Pipeline Products by Development Stage 8
Xeltis AG Pipeline Products Summary by Development Stage 9
Xeltis AG Ongoing Clinical Trials by Trial Status 10
Xeltis AG Ongoing Clinical Trials Summary 11
Endogenous Tissue Restoration (ETR) Cardiovascular Graft - Product Status 12
Endogenous Tissue Restoration (ETR) Cardiovascular Graft - Product Description 12
Transcatheter Aortic Heart Valve - Product Status 13
Transcatheter Aortic Heart Valve - Product Description 13
Xeltis Pulmonary Valve - Product Status 14
Xeltis Pulmonary Valve - Product Description 14
Xeltis Pulmonary Valve - Initial Safety and Performance of the COR-VP-001 Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis 15
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Feasibility of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction 15
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety and Performance of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction 15
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction 16
Xeltis AG, Key Employees 18
Xeltis AG, Subsidiaries 19
Glossary 25
List of Figures
Xeltis AG Pipeline Products by Equipment Type 5
Xeltis AG Pipeline Products by Development Stage 8
Xeltis AG Ongoing Clinical Trials by Trial Status 10

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report